| Expression pattern: |
UP |
| Associated gene: |
BRD4 |
| Associated microRNA: |
miR-223-3p |
| Biological function: |
circ-CCT3 promotes bortezomib resistance in multiple myeloma; circ-CCT3 knockdown reduces IC50 and cell viability, promotes cell cycle arrest and apoptosis, and inhibits proliferation and migration in bortezomib-resistant multiple myeloma cells. |
| Molecular mechanism: |
circ-CCT3 acts through a ceRNA-like mechanism by sponging miR-223-3p to upregulate BRD4, thereby enhancing bortezomib resistance in multiple myeloma. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); migration (promotes); apoptosis (inhibits); cell cycle (other); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Clinical Sample Validation; Transfection; CCK8; Cell Cycle Assay; Annexin V/PI Flow Cytometry; EdU Staining; Wound Healing Assay; Western Blot; Luciferase Reporter Assay; Bioinformatics Analysis |
| Clinical significance: |
circ-CCT3 may serve as a promising biomarker and potential target for improving bortezomib sensitivity and overcoming chemoresistance in multiple myeloma. |
| Description: |
circ-CCT3 is up-regulated in multiple myeloma, especially in bortezomib-resistant patients and cells. It promotes bortezomib resistance by sponging miR-223-3p and upregulating BRD4; circ-CCT3 knockdown increases bortezomib sensitivity, induces apoptosis and cell cycle arrest, and inhibits proliferation and migration. |
| Confidence score: |
0.7181 |